Catalyst Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare neuromuscular and neurological diseases; its core products include FIRDAPSE (amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged six years and older, FYCOMPA (perampanel) for partial-onset and primary generalized tonic-clonic seizures in epilepsy patients aged four and 12 years or older respectively, and AGAMREE (vamorolone) as a corticosteroid for Duchenne muscular dystrophy (DMD) in patients aged two and older; the company offers these products primarily in the United States with sub-licensing in Canada and Japan for select therapies and maintains a robust patient support services suite to ensure accessibility. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals operates with approximately 250 employees and targets underserved rare disease markets including congenital myasthenic syndromes, MuSK-antibody positive myasthenia gravis, spinal muscular atrophy, and infantile spasms through strategic partnerships and ongoing clinical evaluations. Recent developments include the August 2024 initiation of the SUMMIT study for AGAMREE to assess long-term efficacy as monotherapy or in combination and explore additional indications, a July 2024 exclusive sub-license agreement with KYE Pharmaceuticals for AGAMREE commercial rights in Canada, a January 2025 patent settlement with Teva Pharmaceuticals resolving FIRDAPSE generic challenges, approval of FIRDAPSE in Japan in 2024 following prior North American commercialization milestones, prior-year acquisitions of U.S. rights to FYCOMPA from Eisai and North American rights to AGAMREE from Santhera with subsequent U.S. launch, and a $200 million share repurchase program announced in October 2025 backed by over $650 million in cash reserves and no debt as of mid-2025.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease